Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Botanical Supplement Mitigates Menopausal Vasomotor Symptoms - Nutraceuticals World

What are you searching for?

Sign in
Research

Botanical Supplement Mitigates Menopausal Vasomotor Symptoms

Bonafide's Thermella, a formulation of green tea extract, curcumin, and phycocyanin, uniquely targets the neurokinin pathway to reduce hot flashes.

Author Image

By: Mike Montemarano

Associate Editor, Nutraceuticals World

A botanical supplement marketed as Thermella by Bonafide was shown in a recent randomized, double-blind, placebo-controlled study to relieve hot flashes in women experiencing menopause. The findings were published in Maturitas.

The finished product, which is a formulation of 600 mg of Longvida curcumin extract, 150 mg of decaffeinated green tea extract, and 85 mg of phycocyanin spirulina extract, was shown in vivo to inhibit the neurokinin 3 receptor activity, modulating temperature-regulating neurons in the brain by blocking neurokinin-B.

The present study involved 68 menopausal women with 5 or more moderate-to-severe hot flashes daily. Participants received either the supplement or a placebo for 12 weeks. They were evaluated for changes in daily vasomotor symptom frequency and score on the Hot Flash Related Daily Interference Scale (HFRDIS), Menopause-Specific Quality of Life (MENQOL), and the Pittsburgh Sleep Quality Index (PSQI). Serum estrogen and liver function were assessed in a subgroup of participants.

BNI supplementation reduced VMS frequency by an average of 2.2 hot flashes per day, compared to 0.003 for the placebo, corresponding to a 47.7% relative decrease. HFRDIS was improved in the BNI group (p=0.037) with a significant reduction in all subscales. No significant differences were observed in the MENQOL or PSQI. No changes in serum estradiol or liver function were detected, and the supplement was well-tolerated with no difference in adverse events between groups.

“Among women seeking care for vasomotor symptoms, over 60% concurrently use a plant-based supplement,” the authors wrote. “Although not currently endorsed by major society guidelines, there is broadening acceptance of complementary herbal and nutraceutical strategies within a shared decision-making framework, particularly among women ineligible for [hormonal therapy].”

The present findings, according to the authors, “position neurokinin modulation as a practical strategy for women seeking effective alternatives to hormone therapy or prescription neurokinin antagonists.”

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters

Topics